Site Search
Displaying results 121 - 130 of 573
Resource | Guidelines,
Although much has been written on HIV-sensitive social protection, there is insufficient guidance on how to bring to scale what works in the context of different HIV epidemics and for different populations. This document seeks to fill this gap. It provides guidance to governments, people living with, at risk of or affected by HIV, policy-makers, and other stakeholders on how to intensify the integration of HIV with social protection and other programmes for ending poverty and inequality towards ending AIDS. It summarizes relevant evidence on social protection, including cash transfers, and on how social protection contributes to the AIDS response. It presents a brief account of the status of progress of Member States in meeting the HIV and social protection target of the 2016 Political Declaration on AIDS. It provides guidance for leveraging and scaling up social protection—in particular, social safety nets, financial incentives and social services—towards achieving the goal of ending AIDS. It does not focus on social security and labour market polices.
Resource | Publications,
The consultation was convened in Malaysia (Putrajaya, 27 to 28 February 2018) by the Malaysian Ministry of Health and WHO to discuss potential approaches for validation of mother-to-child transmission of hepatitis B inviting national and international experts.
Resource | Guidelines,
In 2016, WHO published updated consolidated guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection. These guidelines included recommendations on the choice of ARV drugs for first- and second-line antiretroviral therapy (ART). An efavirenz (EFV 600 mg)-based regimen was recommended as the preferred first-line regimen, with a dolutegravir (DTG)- or efavirenz (400 mg)-based regimen recommended as alternative options because of limited efficacy and safety data in pregnancy and when taken concomitantly with tuberculosis (TB) treatment. ART recommendations for children remained unchanged in 2016 compared with 2013 because of lack of approved DTG dosing for use in children.
Resource | Publications,
This report updates the first edition, published in 2016, and reviews the progress countries have made in expanding access to life-saving DAAs. The report reviews the main challenges countries face and describes recent developments in relation to five key factors that determine access to DAA medicines: affordability, quality assurance, regulatory approval, government commitment and financing. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.
Resource | Fact Sheets,
In 2016, the Kingdom of Thailand formally decided to re-allocate responsibility for drug dependence treatment from the Ministry of Justice to the Ministry of Public Health by the end of 2018.
This paper offers a brief analysis of these two challenges in light of current policies and practices, along with recommendations for overcoming them to ensure the implementation of a drug treatment system that can result in improved health and human rights outcomes for people who use drugs and people dependent on drugs.
Resource | Guidelines,
The emergence of drug-resistant TB is a major global health concern, which threatens the ambitious goals and progress set under the End TB Strategy. Isoniazid-resistant TB, which is present in 8% of TB cases worldwide, reduces treatment success in patients treated with the standard 6-month first-line regimen.
Resource | Guidelines,
These guidelines provide recommendations and good practice guidance on the optimal approach to diagnosing cryptococcal meningitis, strategies for preventing invasive cryptococcal disease through cryptococcal antigen screening and pre-emptive fluconazole therapy, treating cryptococcal meningitis with combination antifungal therapy regimens, preventing, monitoring and managing amphotericin B drug toxicity, recommendations against adjunctive therapy with systemic corticosteroids and recommendations on the timing of antiretroviral therapy (ART) initiation.
Resource | Publications,
The report examines critical developments on the death penalty for drug offences in law and practice worldwide, revealing one central and unsettling tension: the situation is at once improving and getting worse.
On the one hand, alongside important legal and policy changes, executions for drugs in many High Application States have been steadily declining since 2015. At the same time, political support for the abolition of the death penalty for drug offences has been gathering global momentum. On the other hand, however, these recent signs of progress are being eclipsed by the dramatic surge in extrajudicial executions for drugs in the Philippines, and the ripple effects this is having in the region and beyond.
Resource | Guidelines,
This technical update provides public health officials with guidance on applying HIV incidence assays and testing algorithms for recent HIV infection in order to monitor the HIV epidemic and assess the impact of interventions. A major theme of this update is the importance of calibrating two of the key performance characteristics of recent testing infections algorithms - mean duration of recent infection and false recent ratio - to account for the context in which the testing is being done. This technical update also describes several emerging use cases in the application of recent infection testing algorithms and tests, including those for individual-level use. A final section on further research directions is provided to highlight areas that still require investigation.
Resource | Publications,
The INCB Annual Report, prepared in accordance with the international drug control treaties, examines the global drug control situation, and makes recommendations to Governments and regional and international organizations. The thematic chapter of the INCB Annual Report for 2017 focuses on treatment, rehabilitation and social reintegration for drug use disorders as essential components of drug demand reduction. The Report also focuses on the linkages between human rights and drug control policy, particularly as 2018 marks the occasion of the seventieth anniversary of the United Nations Universal Declaration on Human Rights. The Report's review of the functioning of the international drug control system also contains a number of key policy positions of the Board, for example on the non-medical use of cannabis and "drug consumption rooms".